Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.

The 2 most common genetic polymorphisms that predispose to a first episode of venous thromboembolism (VTE) are factor V Leiden (FVL) and prothrombin G20210A. However, the effect of these polymorphisms on the risk of recurrent VTE is unclear. We performed a meta-analysis to obtain best estimates of the relative risk of recurrent VTE associated with these genetic polymorphisms. Electronic and manual searches were used to identify cohort studies of patients with a first episode of VTE that reported the incidence of objectively confirmed recurrence following discontinuation of anticoagulation among those with or without heterozygous FVL or prothrombin G20210A polymorphism. Thirteen reports fulfilled our criteria for inclusion. Pooled results from 10 studies involving 3104 patients with first-ever VTE revealed that FVL was present in 21.4% of patients (95% confidence interval [CI], 20%-23%) and associated with an increased odds of recurrent VTE of 1.41 (95% CI, 1.14-1.75; P = .08 for heterogeneity). Pooled results from 9 studies involving 2903 patients with first-ever VTE revealed that prothrombin G20210A was present in 9.7% of patients (95% CI, 9%-11%) and associated with an increased odds of recurrent VTE of 1.72 (95% CI, 1.27-2.31; P = .19). The estimated population-attributable risk of recurrence for FVL was 9.0% (95% CI, 4.5%-13.2%) and for prothrombin G20210A was 6.7% (95% CI, 3.4%-9.9%). Heterozygous FVL and prothrombin G20210A are each associated with a significantly increased risk of recurrent VTE after a first event, but the magnitude of the increase in risk is modest and by itself is unlikely to merit extended-duration anticoagulation. These data call into question the cost-effectiveness of routine testing for these common inherited thrombophilic polymorphisms among patients with a first episode of VTE.

[1]  E. Minar,et al.  Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism , 2004 .

[2]  C. Mannhalter,et al.  Probability of Recurrence of Thrombosis in Patients with and without Factor V Leiden , 1996, Thrombosis and Haemostasis.

[3]  P. Ridker,et al.  Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.

[4]  H. Blom,et al.  Interaction Between Hyperhomocysteinemia, Mutated Methylenetetrahydrofolatereductase (MTHFR) and Inherited Thrombophilic Factors in Recurrent Venous Thrombosis , 2002, Thrombosis and Haemostasis.

[5]  P. Ridker,et al.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism☆ , 2003 .

[6]  G Leone,et al.  The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. , 2001, British journal of haematology.

[7]  E. Minar,et al.  The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden , 1997, Thrombosis and Haemostasis.

[8]  Giancarlo Agnelli,et al.  Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[9]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[10]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[11]  G. Barosi,et al.  Extended Anticoagulation for Prevention of Recurrent Venous Thromboembolism in Carriers of Factor V Leiden , 2000, Thrombosis and Haemostasis.

[12]  I. Martinelli.  Pros and cons of thrombophilia testing: pros , 2003, Journal of thrombosis and haemostasis : JTH.

[13]  B. Giusti,et al.  Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. , 2003, The American journal of medicine.

[14]  P. Ridker,et al.  G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. , 2001, Journal of the American College of Cardiology.

[15]  P. Reitsma,et al.  Geographic Distribution of the 20210 G to A Prothrombin Variant , 1998, Thrombosis and Haemostasis.

[16]  Klaus Lechner,et al.  The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. , 2002, Archives of internal medicine.

[17]  M. Margaglione,et al.  Coexistence of Factor V Leiden and Factor II A20210 Mutations and Recurrent Venous Thromboembolism , 1999, Thrombosis and Haemostasis.

[18]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[19]  S. Machin,et al.  Pros and cons of thrombophilia testing: cons , 2003, Journal of thrombosis and haemostasis : JTH.

[20]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[21]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[22]  F. Bernardi,et al.  Predictive Value of D‐Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia , 2003, Circulation.

[23]  O. Linder,et al.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. , 1997, The New England journal of medicine.

[24]  T. Baglin,et al.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study , 2003, The Lancet.

[25]  M. Prins,et al.  The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders , 2002, British journal of haematology.

[26]  E. Minar,et al.  The risk of recurrent venous thromboembolism in men and women. , 2004, The New England journal of medicine.

[27]  CliveKearon.  Long-Term Management of Patients After Venous Thromboembolism , 2004 .

[28]  Bradley Flansbaum,et al.  Clinical factors and recurrent venous thrombotic events. , 2005, JAMA.

[29]  E. Minar,et al.  The Risk of Early Recurrent Venous Thromboembolism after Oral Anticoagulant Therapy in Patients with the G20210A Transition in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[30]  The Procare Group.  Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients? , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[31]  T. Baglin,et al.  Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors , 1998, British journal of haematology.

[32]  Frits R Rosendaal,et al.  Thrombophilia, clinical factors, and recurrent venous thrombotic events. , 2005, JAMA.

[33]  M. Prins,et al.  The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). , 1997, The New England journal of medicine.

[34]  B. Wiman,et al.  The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[35]  D. Ost,et al.  Duration of anticoagulation following venous thromboembolism: a meta-analysis. , 2005, JAMA.

[36]  H. Büller,et al.  Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model , 2003, Journal of thrombosis and haemostasis : JTH.

[37]  A. Berrebi,et al.  Causes and outcome of deep-vein thrombosis in otherwise-healthy patients under 50 years. , 1997, QJM : monthly journal of the Association of Physicians.

[38]  P. Prandoni,et al.  Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors. , 2003, Thrombosis and haemostasis.

[39]  G Leone,et al.  The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. , 1999, The New England journal of medicine.

[40]  Giuseppe Leone,et al.  Screening for inherited thrombophilia: indications and therapeutic implications. , 2002, Haematologica.

[41]  M. Prins,et al.  Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutationRisk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis , 2000 .

[42]  N. Dzimiri,et al.  World distribution of factor V Leiden , 1996, The Lancet.